Topical Pain Management
What is prescription cannabidiol?
Cannabidiol (CBD) and its chemical relatives are not new drugs, but their properties are studied now more than ever before. CBD is currently available in an FDA-approved drug to treat seizure disorders, and there seems to be more research indicating possible effectiveness in treatments for a wide range of conditions. Working in the endocannabinoid system, CBD may be useful for colitis1, anxiety disorders2, neurodegenerative disease3, neuro-inflammation4, and pain relief5. Cannabinoid receptors are found throughout the natural pain pathway in the body, meaning CBD may be useful for a variety of painful symptoms. Our sourced non-hemp derived CBD is currently the only marketed active pharmaceutical ingredient used for compounding in many different formulations, including topical pain products.
WHAT TO EXPECT IN THE BOX
First approved in the United States in 1977, baclofen is described as a centrally acting muscle relaxant that has been shown to inhibit spinal reflexes. It is used to treat symptoms such as muscle spasm, muscle pain, and muscle stiffness by interacting with GABA type-B receptors that are found throughout the nervous system. Due to these actions and other unknown actions, it has also been shown to be effective in treating neuralgia, or nerve pain.
Approved for use in 1980 in the United States, ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that acts to inhibit the body’s production of prostaglandin. This means that ketoprofen has pain relieving and fever reducing effects on the body. It is known to be effective for conditions such as mild to moderate pain, osteoarthritis, and rheumatoid arthritis. Ketoprofen has been shown in medical journals to be effective as a topical product for a range of musculoskeletal conditions.
Probably one of the most well-known topical anesthetic agents in the United States, Lidocaine was first introduced in 1948. Lidocaine works by inhibiting nerve impulse conduction which provides its numbing effect on local areas of the body. It is available commercially in several forms including a patch, cream, ointment, solution, and spray. Lidocaine is known to be effective for topical treatment of many different types of painful situations when used appropriately.
Cannabidiol is a chemical compound currently marketed only by Professional Compounding Centers of America (or PCCA). It is considered a prescription-only drug by the FDA. Cannabidiol is synthetic and is not derived from hemp or marijuana with a THC content of <0.1% and is not considered a controlled substance by the DEA and is not expected to cause a positive THC or THC metabolite in a urine drug test. It is the active ingredient in the FDA-approved drug Epidiolex® which is currently marketed for seizure control. Cannabidiol works on the endocannabinoid receptors that occur in the body, most commonly in the nervous system and the immune system. It is believed that this drug works to modulate how we perceive inflammation and can help control the inflammatory response across a variety of pain disorders including arthritis with a favorable topical side-effect profile.
Lipoderm® Anhydrous is a proprietary base that has been intensively studied to validate drug transport from the base through human skin. It is formulated without soy, parabens, almond, egg, fish, gluten, milk, peanut, pecan, or walnut and is high in natural ingredients such as berry wax, vitamin E, and seed oils. It is high in unsaturated fatty acids like omega-3. It is an ideal base for deep-penetrating topical formulas to enhance local absorption of active pharmaceutical ingredients. It has a smooth and silky feel for patient comfort.
- Epocrates monographs
- Cannabinoids and Pain: Sites and Mechanisms of Action. Starowicz K, Finn DP, Adv Pharmacol. 2017;80:437-475.
1. Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology. 2012;89(3-4):149–155. doi:10.1159/000336871
2. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients. Mateus M Bergamaschi, et al, Neuropsychopharmacology, Feb 2011
3. Ashton JC, Glass M. The Cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 2007;5:73–80.
4. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression, G Esposito, et al, British Journal of Pharmacology, January 2009
5. Cannabinoids and Pain: Sites and Mechanisms of Action. Starowicz K, Finn DP, Adv Pharmacol. 2017;80: 437-475.
6. Transdermal cannabidiol reduces inflammation and pain-related behaviors in a rat model of arthritis, D.C. Hammell, et al, European Journal of Pain, Oct 2015